Eli Lilly
-
Eli Lilly Surges After FDA Approves Foundayo Obesity Pill
Eli Lilly shares rose 4% following FDA approval of Foundayo, an oral GLP-1 medication for weight loss, signaling a major shift in the obesity treatment market.
-
Eli Lilly Stock Faces ‘Reduce’ Warning Amid Mixed Data
Eli Lilly stock navigates a volatile week as positive clinical data meets a sharp analyst downgrade, sparking debate over the future of the obesity drug market.
-
Novo Nordisk Boosts Oral GLP-1 Production Amid Intensifying Competition
Novo Nordisk commits €432 million to scale oral GLP-1 production in Ireland, solidifying its chronic disease treatment focus.
-
Eli Lilly Widens Obesity Drug Lead with Zepbound Wins
Eli Lilly solidified its dominance in the obesity drug market on Monday. New trial data showed Zepbound’s superior efficacy, and a multi-dose KwikPen launched.
-
Novo Nordisk Stock Falls on Disappointing CagriSema Trial Results
Novo Nordisk A/S (NVO) shares dropped pre-market after its experimental obesity drug, CagriSema, failed to meet its primary endpoint in a Phase 3 trial, impacting its competitive standing.
-
Novo Nordisk CEO Unveils Aggressive Strategy to Reclaim GLP-1 Market Lead, Targets 2 Billion People
Novo Nordisk’s new CEO Maziar Mike Doustdar outlines a bold three-pronged strategy for 2026, aiming to reclaim market dominance in the GLP-1 obesity drug sector from rival Eli Lilly. The plan focuses on commercial execution, pipeline progression, and a return…
-
Eli Lilly Stock Surges After Record Q3 Earnings and Raised Guidance
Eli Lilly delivered a standout third quarter, beating Wall Street forecasts on both earnings and revenue, fueled by soaring demand for diabetes and obesity treatments. The company raised its full-year guidance, signaling strong growth momentum and investor confidence.
-
Eli Lilly Stock Surges Amid FDA Wins and Manufacturing Expansion
Eli Lilly stock jumps as FDA approvals, major contracts, and strategic U.S. investments reshape its financial landscape, signaling a new era for the pharma giant.